In the bevacizumab group, performance status ≥2, poorly differentiated tumor, absence of metastasectomy, and elevated baseline serum carcinoembryonic antigen (CEA) or lactate dehydrogenase levels were identified as independent poor prognostic factors for OS by univariate and multivariate analyses. The gene discussed is CEACAM5; the disease is neoplasm.